Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years

American Journal of Neuroradiology

Volumn 34, Issue 10, 2013, Pages 1931-1939

  Zivadinov, R ^a,b   Bergsland, N ^a   Dolezal, O ^c   Hussein, S ^a   Seidl, Z ^c   Dwyer, M G ^a   Vaneckova, M ^c   Krasensky, J ^c   Potts, J A ^e   Kalincik, T ^c,d   Havrdova E ^c   Horakova D ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN SIZE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; FEMALE; GRAY MATTER; HUMAN; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; THALAMUS; WHITE MATTER;

ADJUVANTS, IMMUNOLOGIC; ADULT; ATROPHY; AZATHIOPRINE; CEREBRAL CORTEX; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; STEROIDS; THALAMUS; YOUNG ADULT;

EID: 84885413852     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3503     Document Type: Article

References (44)

1. Geurts JJ, Stys PK, Minagar A, et al. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009;282: 12-20
2. Zivadinov R, Pirko I. Advances in understanding gray matter pathology in multiple sclerosis: are we ready to redefine disease pathogenesis? BMC Neurol 2012;12:9
3. Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007;68: 634-42
4. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64: 255-65
5. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64: 247-54
6. Horáková D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 2008;79: 407-14
7. Hulst HE, Geurts JJ. Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol 2011;11:153
8. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012;12:11
9. Bozzali M, Cercignani M, Sormani MP, et al. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 2002;23: 985-88
10. Audoin B, Ranjeva JP, Duong MV, et al. Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging 2004;20: 765-71
11. Bö L, Geurts JJ, Mork SJ, et al. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 2006;183: 48-50
12. Horáková D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009;282: 112-19
13. Tedeschi G, Dinacci D, Comerci M, et al. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Mult Scler 2009;15: 204-11
14. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66: 1144-50
15. Jure L, Zaaraoui W, Rousseau C, et al. Individual voxel-based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis. J Magn Reson Imaging 2010;32: 424-28
16. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254: 1212-20
17. Henry RG, Shieh M, Okuda DT, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79: 1236-44
18. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17: 1098-106
19. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77: 257-63
20. Bergsland N, Horáková D, Dwyer MG, et al. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2012;33: 1573-78
21. Benedict RH, Ramasamy D, Munschauer F, et al. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry 2009;80: 201-06
22. Benedict R, Bruce J, Dwyer M, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63: 1301-06
23. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999;53: 1698-704
24. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsingMSdecreases during treatment with IFN-beta-1a. Neurology 2005;64: 236-40
25. Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007;13: 490-501
26. Nakamura K, Rudick RA, Lee JC, et al. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis. Neurology 2010;74:A407 (abstract)
27. Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009;15: 965-76
28. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57: 1239-47
29. Jenkinson M, Bannister P, Brady M, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17: 825-41
30. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59: 331-39
31. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17: 479-89
32. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm. IEEE Trans Med Imaging 2001;20: 45-57
33. Patenaude B, Smith SM, Kennedy DN, et al. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56: 907-22
34. Kalincik T, Horáková D, Dolezal O, et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg 2012;114: 940-46
35. Fitzmaurice GM, Laird N, Ware JH. Applied Longitudinal Analysis. Hoboken, New Jersey: John Wiley and Sons; 2004
36. Zivadinov R, Reder A, Filippi M, et al. Mechanisms of action of disease- modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71: 136-44
37. Turner B, Lin X, Calmon G, et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003;9: 21-27
38. Martola J, Bergstrom J, Fredrikson S, et al.Alongitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images. Neuroradiology 2010;52: 109-17
39. Cherubini A, Peran P, Caltagirone C, et al. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 2009;48: 29-36
40. Minagar A, Barnett M, Benedict R, et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging and clinical aspects. Neurology 2013;80: 210-19
41. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39: 285-94
42. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group.Ann Neurol 1998;43: 79-87
43. Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000;6: 365-72
44. Horáková D, Kalincik T, Dolezal O, et al. Early predictors of nonresponse to interferon in multiple sclerosis. Acta Neurol Scand 2012; 126: 390-97